

Author's Proof

Before checking your proof, please read the instructions below.

Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools ([Adobe Help](#)).

Provide your corrections in one single PDF file or post your comments in the Production forum making sure to reference the relevant query/line number, and to upload or post all your corrections directly in the Production forum, to avoid any comments being missed.

We do not accept corrections in the form of edited manuscripts nor via email.

Before you submit your corrections, please make sure that you have checked your proof carefully as once you approve it, you won't be able to make any further corrections.

Submitting your corrections is a 2-step process. First, you need to upload your file(s). Second, you will need to approve your proof or request a new one.

In order to ensure the timely publication of your article, please submit the corrections within 48 hours. After submitting, do not email or query asking for confirmation of receipt.

If you have any additional questions, contact cellbiology.production.office@frontiersin.org.

Quick Check-List

- **Author names** - Complete, accurate and consistent with your previous publications.
- **Affiliations** - Complete and accurate. Follow this style when applicable: Department, Institute, University, City, Country.
- **Tables** - Make sure our formatting style did not change the meaning/alignment of your Tables.
- **Figures** - Make sure we are using the latest versions.
- **Funding and Acknowledgments** - List all relevant funders and acknowledgments.
- **Conflict of Interest** - Ensure any relevant conflicts are declared.
- **Supplementary files** - Ensure the latest files are published and that no line numbers and tracked changes are visible.
Also, the supplementary files should be cited in the article body text.
- **Queries** - Reply to all typesetters queries below.
- **Content** - Read all content carefully and ensure any necessary corrections are made.

Author Queries Form

Query No.	Details Required	Author's Response
Q1	The citation and surnames of all of the authors have been highlighted. Check that they are correct and consistent with the authors' previous publications, and correct if need be. Please note that this may affect the indexing of your article in repositories such as PubMed.	
Q2	Please ask the following authors to register with Frontiers (at https://www.frontiersin.org/Registration/Register.aspx) if they would like their names on the article abstract page and PDF to be linked to a Frontiers profile. Please ensure to provide us with the profile link(s) when submitting the proof corrections. Non-registered authors will have the default profile image displayed. "Federico Giulitti" "Simonetta Petrunaro"	

Query No.	Details Required	Author's Response
	<p>“Eugenio Gaudio” “Elio Ziparo.”</p>	
Q3	<p>Confirm that all author affiliations are correctly listed. Note that affiliations are listed sequentially as per journal style and requests for non-sequential listing will not be applied.</p>	
Q4	<p>Confirm that the email address in your correspondence section is accurate.</p>	
Q5	<p>If you decide to use previously published, copyrighted figures in your article, please keep in mind that it is your responsibility, as the author, to obtain the appropriate permissions and licenses and to follow any citation instructions requested by third-party rights holders. If obtaining the reproduction rights involves the payment of a fee, these charges are to be paid by the authors.</p>	
Q6	<p>Ensure that all the figures, tables and captions are correct, and that all figures are of the highest quality/resolution.</p>	
Q7	<p>Verify that all the equations and special characters are displayed correctly.</p>	
Q8	<p>Confirm that the Data Availability statement is accurate. Note that we have used the statement provided at Submission. If this is not the latest version, please let us know.</p>	
Q9	<p>Confirm that the details in the “Author Contributions” section are correct and note that we have added the sentence “All authors contributed to the article and approved the submitted version.”</p>	
Q10	<p>Ensure to add all grant numbers and funding information, as after publication this will no longer be possible. All funders should be credited and all grant numbers should be correctly included in this section.</p>	
Q11	<p>Ensure that any supplementary material is correctly published at this link: https://www.frontiersin.org/articles/10.3389/fcell.2021.629182/full#supplementary-material Provide new files if you have any corrections and make sure all Supplementary files are cited. Please also provide captions for these files, if relevant. Note that ALL supplementary files will be deposited to FigShare and receive a DOI. Notify us of any previously deposited material.</p>	
Q12	<p>Confirm whether the insertion of the article title is correct.</p>	
Q13	<p>Confirm that the keywords are correct and keep them to a maximum of eight and a minimum of five. (Note: a keyword can be comprised of one or more words.) Note that we have used the keywords provided at Submission. If this is not the latest version, please let us know.</p>	
Q14	<p>Check if the section headers (i.e., section leveling) were correctly captured.</p>	

Query No.	Details Required	Author's Response
Q15	Confirm that the short running title is correct, making sure to keep it to a maximum of five words.	
Q16	Confirm if the text included in the Conflict of Interest statement is correct.	
Q17	Confirm whether the insertion of figure citations in the sentence "... reduces the migration of both..." is fine.	
Q18	Confirm whether the insertion of the "Funding" section is fine.	
Q19	Provide doi for the following references. "Jarc and Petan, 2019; Yao et al., 2011."	
Q20	Provide the volume number for "Safa, 2013."	
Q21	Confirm whether the insertion of citation "Figures 1, 2" is fine.	



Anti-tumor Effect of Oleic Acid in Hepatocellular Carcinoma Cell Lines via Autophagy Reduction

Federico Giulitti, Simonetta Petrunaro, Sara Mandatori[†], Luana Tomaipitnca, Valerio de Franchis, Antonella D'Amore, Antonio Filippini*, Eugenio Gaudio, Elio Ziparo and Claudia Giampietri*

Department of Anatomical, Histological, Forensic Medicine, and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy

OPEN ACCESS

Edited by:

Lucia Latella,
Italian National Research Council, Italy

Reviewed by:

Emanuele Berardi,
Universiteit Hasselt, Belgium
Laura Belloni,
Sapienza University of Rome, Italy

*Correspondence:

Claudia Giampietri
claudia.giampietri@uniroma1.it
Antonio Filippini
antonio.filippini@uniroma1.it

[†] Present address:

Sara Mandatori,
Neuroinflammation Unit, Faculty of
Health and Medical Sciences, Biotech
Research and Innovation Centre
(BRIC), Copenhagen Biocentre,
University of Copenhagen,
Copenhagen, Denmark

Specialty section:

This article was submitted to
Cell Death and Survival,
a section of the journal
Frontiers in Cell and Developmental
Biology

Received: 13 November 2020

Accepted: 14 January 2021

Published: xx January 2021

Citation:

Giulitti F, Petrunaro S, Mandatori S,
Tomaipitnca L, de Franchis V,
D'Amore A, Filippini A, Gaudio E,
Ziparo E and Giampietri C (2021)
Anti-tumor Effect of Oleic Acid in
Hepatocellular Carcinoma Cell Lines
via Autophagy Reduction.
Front. Cell Dev. Biol. 9:629182.
doi: 10.3389/fcell.2021.629182

Oleic acid (OA) is a component of the olive oil. Beneficial health effects of olive oil are well-known, such as protection against liver steatosis and against some cancer types. In the present study, we focused on OA effects in hepatocellular carcinoma (HCC), investigating responses to OA treatment (50–300 μ M) in HCC cell lines (Hep3B and Huh7.5) and in a healthy liver-derived human cell line (THLE-2). Upon OA administration higher lipid accumulation, perilipin-2 increase, and autophagy reduction were observed in HCC cells as compared to healthy cells. OA in the presence of 10% FBS significantly reduced viability of HCC cell lines at 300 μ M through Alamar Blue staining evaluation, and reduced cyclin D1 expression in a dose-dependent manner while it was ineffective on healthy hepatocytes. Furthermore, OA increased cell death by about 30%, inducing apoptosis and necrosis in HCC cells but not in healthy hepatocytes at 300 μ M dosage. Moreover, OA induced senescence in Hep3B, reduced P-ERK in both HCC cell lines and significantly inhibited the antiapoptotic proteins c-Flip and Bcl-2 in HCC cells but not in healthy hepatocytes. All these results led us to conclude that different cell death processes occur in these two HCC cell lines upon OA treatment. Furthermore, 300 μ M OA significantly reduced the migration and invasion of both HCC cell lines, while it has no effects on healthy cells. Finally, we investigated autophagy role in OA-dependent effects by using the autophagy inducer torin-1. Combined OA/torin-1 treatment reduced lipid accumulation and cell death as compared to single OA treatment. We therefore concluded that OA effects in HCC cells lines are, at least, in part dependent on OA-induced autophagy reduction. In conclusion, we report for the first time an autophagy dependent relevant anti-cancer effect of OA in human hepatocellular carcinoma cell lines.

Keywords: lipid droplets, autophagy, fatty acids, cell death, cancer

INTRODUCTION

In the last years different research groups investigated the relationships between fatty acids and solid tumors. Fatty acids are major components of biological membranes and play important roles in the intracellular signaling pathways. They are chemically classified as saturated and unsaturated (monounsaturated and polyunsaturated) fatty acids and their structure affects their biological effects. One of the most abundant fatty acid is the monounsaturated fatty

acid Oleic Acid (OA), representing the main component of olive oil (70–80%). Olive oil has beneficial effects in counteracting liver steatosis and cardiovascular diseases (Perez-Martinez et al., 2011; Perdomo et al., 2015; Zeng et al., 2020). OA effects on cancer cells are not completely elucidated although they seem to be different depending on cancer cell types (Sales-Campos et al., 2013; Maan et al., 2018). Upon OA administration in *in vitro* set up, lipid droplets (LD) formation occurs within the cells (Rohwedder et al., 2014) and inside these compartments neutral lipids are concentrated with mechanisms still largely unclear (Fujimoto et al., 2006). Most eukaryotic cells can store excess neutral lipids within LD (consisting mainly of triglycerides and cholesteryl esters), and release them when necessary, depending on cellular needs. This property is particularly important in cells exposed to feeding periods followed by starvation periods, such as cancer cells (Jarc and Petan, 2019). In the present study we investigated *in vitro* the effects of OA in HCC models. Previous works have shown that OA treatment leads to a massive lipid accumulation in hepatocytes cell lines (i.e., LO2 and HepG2 cells) associated with cell viability reduction (Yao et al., 2011). We tested whether OA affects lipid accumulation, autophagy and cell death in different HCC cell lines compared to immortalized healthy hepatocytes. Autophagy is a catabolic process essential to maintain cellular homeostasis; it allows the turnover of cellular components including LD (Giampietri et al., 2017). In the autophagy-mediated lipolytic process, LD are associated with the autophagosome protein microtubule-associated protein light chain 3 (LC3) and then are delivered to lysosomes (Singh et al., 2009). Therefore, autophagy plays a crucial role in LD degradation regulating fatty acids mobilization. On the contrary, autophagy impairment, achieved by genetic knockdown of autophagy genes (i.e., atg5 or atg7), significantly increases hepatic lipid stores (Amir and Czaja, 2011). Autophagy is the main cellular response to nutrients deprivation (Denton et al., 2012) and plays a dual role in neoplastic transformations (Mizushima, 2007; D'Arcangelo et al., 2018). Autophagy upregulation under chemotherapy treatment may increase cancer cell survival (Ding et al., 2011). Autophagy inhibition leads to cell death promotion and cell growth inhibition, and its activation induces cell proliferation in HCC (Chava et al., 2017). For such reasons inhibiting the autophagy pathways might be crucial to induce cancer cell death (Tomaiipinca et al., 2019). Relatively little is known about the molecular mechanisms underlying the OA effects in liver cancer cells and the role of autophagy (Li et al., 2014; Maan et al., 2018). Evidences exist showing an inverse relation in liver between levels of autophagy and perilipin-2, a constitutive protein of LD. High levels of Perilipin-2 inhibit LD degradation by decreasing autophagy while perilipin-2 deficiency increases autophagy leading to LD breakdown (Singh et al., 2009; Sanchez-Martinez et al., 2015; Tsai et al., 2017). Further evidences demonstrated a direct relationship between OA and perilipin-2 accumulation in tumors such as glioblastoma, confirming the relationship between OA and LD storage (Taib et al., 2019). Conversely, the role LD store plays on controlling HCC growth is still partially unknown. In the present work we investigated LD accumulation in HCC cell lines (Hep3B and Huh7.5) vs. immortalized healthy hepatocytes (THLE-2) after OA treatment, with a focus on autophagy role. We report an anti-tumor action

of OA in HCC and a specific OA effect on lipid accumulation, viability, proliferation, migration and invasion, at least partially dependent on reduced autophagy.

MATERIALS AND METHODS

Cells Culture and Reagents

Hep3B and Huh7.5 cell lines were kindly donated by Professor Maria Rosa Ciriolo “Tor Vergata” University of Rome.

The two HCC cell lines display respectively deletion (i.e., Hep3B) or point p53 mutation (i.e., Huh7.5) as tumor suppressor p53 is one of the most frequently mutated genes in liver cancer (Rebouissou and Nault, 2020). Cells were cultured in DMEM (Gibco-Invitrogen, Carlsbad, CA, USA) containing high glucose enriched with 10% fetal bovine serum, glutamine (2 mmol/l), in presence of penicillin (100 U/ml) and streptomycin (100 µg/ml). Cells were maintained at 37°C in a humidified 5% CO₂ atmosphere. OA was purchased from Sigma-Aldrich (Milano, Italy) and diluted with 0.1% NaOH, 10% delipidated BSA (Sigma-Aldrich).

Control cell line (THLE-2) was purchased from the American Type Culture Collection (ATCC, Manasses, VA, USA). THLE-2 cells show phenotypic characteristics of normal adult hepatocytes, are non-tumorigenic when injected into athymic nude mice and do not express alpha-fetoprotein (Pfeifer et al., 1993). THLE-2 were cultured with BEGM Bullet Kit (Catalog No. CC-3170) from Lonza (East Rutherford, NJ, USA). The Bullet Kit contains BEBM Basal Medium (CC-3171 Lonza) and supplements. The final growth medium consists of BEBM supplemented with 10% FCS, bovine pituitary gland extract, hydrocortisone, epidermal growth factor (EGF), insulin, triiodothyronine, transferrin, retinoic acid, 6 ng/ml human recombinant EGF (Sigma-Aldrich) and 80 ng/ml o-phosphorylethanolamine (Sigma-Aldrich). THLE-2 cells require a special flask coating medium that consists of the following reagents: a mixture of 0.01 mg/mL fibronectin from human plasma (Sigma-Aldrich), 0.03 mg/mL bovine collagen type I (Sigma-Aldrich) and 0.01 mg/mL bovine serum albumin (Sigma-Aldrich) in BEBM medium. Before seeding, 3 ml of coating medium for a T-75 flask and 1 ml of coating medium for one 6-well plate were applied for 2 min and then aspirated.

ATCC guidelines for culturing THLE-2 are available at: https://www.lgcstandards-atcc.org/products/all/CRL-2706.aspx?geo_country=it#culturemethod.

Hep3B, Huh7.5 and THLE-2 cells were cultured in T-75 flasks and experiments were performed in 6-well plates. The day after plating, cells were treated with OA at different concentration (50, 150, and 300 µM OA) for the indicated time. Bafilomycin A1 was purchased from Sigma-Aldrich and was used at 100 nM during the last 3 h treatment. Torin-1 was purchased from (Tocris, Bristol, UK) and was used during the last 4 h treatment at the concentration of 250 nM for Hep3B and 500 nM for Huh7.5 cell lines.

Western Blotting

Cells were washed two times with pre-chilled PBS (Phosphate Buffered Saline) purchased from Sigma-Aldrich and lysed. Lysis Buffer 10x (Cell Signaling, Danvers, MA, USA) was diluted

in the presence of 2% SDS (Sodium Dodecyl Sulfate) and proteases' inhibitors (Sigma-Aldrich). Lysates were also sonicated through a sonicator (Branson, Danbury, USA) for 10 s at 50% amplitude. Lysates were then incubated for 10 min on ice and then centrifuged at 4°C for 15 min at 14,000 g to remove cell debris.

Protein concentration was determined by micro BCA assay (Pierce, Thermo Scientific, Rockford, IL, USA) and samples were boiled at 95°C for 5 min following Laemmli Buffer addition (0.04% Bromophenol blue, 40% Glycerol, 2% SDS, 20% β -mercaptoethanol, 250 mM Tris HCl pH.6.8, all purchased from Sigma-Aldrich) (Giampietri et al., 2006).

Proteins were separated by SDS-PAGE and transferred on Polyvinylidene fluoride (PVDF) or Nitrocellulose membranes (Amersham Bioscience, Piscataway, NJ, USA). Membranes were probed using the following antibodies: anti- β -Actin-HRP (Sigma-Aldrich 1:10,000); anti-Tubulin (Sigma-Aldrich 1:10,000); anti-LC3 (Cell Signaling 1:1,000); anti-Perilipin-2 (Sigma-Aldrich 1:500); anti-Cleaved caspase-3 (Cell Signaling 1:700); anti-PARP (Cell Signaling 1:1,000); anti-pERK (Cell Signaling 1:1,000); anti-ERK2 (Santa Cruz, Santa Cruz, CA, USA 1:1,000); anti-Bcl-2 (Santa Cruz 1:500); anti-Flip (Cell Signaling 1:1,000); anti-Cyclin D1 (Santa Cruz 1:500); anti-PCNA (Santa Cruz 1:500); anti-Srebp-1 (Santa Cruz sc-13551 1:500); anti PPAR-gamma (Cell Signaling 2443 1:500).

Secondary antibodies were horseradish peroxidase-conjugated anti-mouse or anti-rabbit (Bio-Rad, Hercules, CA, USA). Membranes were washed with Tris-buffered saline (Medicago, Uppsala, Sweden) with 0.1% Tween-20 (Sigma-Aldrich) and developed through the chemiluminescence system (Amersham Bioscience) on the ChemiDoc image analyser (Bio-Rad, Hercules, CA, USA), Image lab software was used for densitometric quantifications.

Oil-Red O Staining

Briefly, a stock oil red solution was prepared diluting 0.7 g Oil Red O with 200 mL isopropanol. A working dilution was then obtained by mixing 6 parts Oil-Red O stock with 4 parts dH₂O. Cells were fixed with 10% formalin 5 min at room temperature. Then fresh formalin was added and incubated 1 h. After formalin removal, cells were washed with 60% isopropanol 5 min at room temperature. After isopropanol removal, oil red working solution was added for 10 min. Cells were then washed with H₂O and analyzed immediately by light microscopy. The Axioskop 2 plus microscope (Carl Zeiss Microimaging, Inc., Milan, Italy) was used. Images were obtained at room temperature using AxioCamHRC camera (Carl Zeiss Microimaging, Inc.) by Axiovision software (version 3.1, Carl Zeiss Microimaging, Inc.). Then, the stained lipid droplets were dissolved in 1.5 ml 100% isopropanol 5 min at room temperature and the absorbance was measured at 500 nm to quantify neutral lipid accumulation.

Alamar Blue Assay

Alamar blue assay was performed using Resazurin sodium salt solution (Sigma-Aldrich). Cells were cultured and treated in 96-well plates as previously described, washed and then Resazurin sodium salt solution was added for 4 h. The solution

was collected and detected using a luminometer (Promega, Madison, WIS, USA) using 580–640 nm emission filter and 520 nm excitation filter.

Cell Viability Assay

Cell viability was performed by counting cells in the presence of trypan blue. Cells were seeded on 6-well plates and incubated at 37°C in 5% CO₂ overnight, then treated with different doses of OA. After OA incubation, cells were detached, volume mixed 1:1 with trypan blue and counted. The percentage of trypan blue positive-dead cells respect to the total cell number was expressed as the viability rate.

Flow Cytometry Cell Cycle and Cell Death Analysis

For cell cycle analysis, cells were treated with OA at a concentration of 300 μ M for 48 h and then the cells were fixed with 70% ethanol, washed three times with PBS and stained for 3 h at room temperature with PBS containing 20 μ g/mL RNase A and 50 μ g/mL propidium iodide (PI). Around 10,000 cells were analyzed using a CyAn ADP flow cytometer (Beckman Coulter, Brea, CA, USA) and FCS express 5 (*De Novo* software, Glendale, CA, USA). The experiment was performed three times with consistent results.

Annexin Pacific Blue /PI kit (Termo Fisher Scientific, Rockford, IL, USA) was employed for the detection of percentage of cell death according to manufacturer's instructions. Cells were treated with OA at the different concentrations into a 6-well plate at the density of 1×10^5 cells/well for 24 h. Double staining was used to identify the cell membrane phosphatidylserine externalization and PI uptake. The results are from three independent experiments ($n = 3$). Samples were run on the CyAn ADP flow cytometer (Beckman Coulter) and analyzed with FlowJo software, version 10.5.3.

Wound-Healing Assay

To evaluate cell migration we performed the wound-healing assay using double well culture inserts (Ibidi GmbH, Martinsried, Germany). Each insert was placed in a 24-well plate, 3.5×10^4 cells were plated into both wells of each insert with 70 μ L medium containing 10% FBS. When cells were confluent, the culture inserts were gently removed and cells were fed with 1% FBS DMEM (CTRL) or treated with OA 300 μ M (in the presence of 1% FBS DMEM). Each well was photographed at 10 \times magnification immediately after insert removal, for the measurement of the wound (cell-free) area (T0 area considered as 100%), and after 24 and 48 h with a Nikon DS-Fi1 camera (Nikon Corporation, Tokyo, Japan). The mean percentage of residual open area compared with the respective cell-free space taken at T0 was calculated using ImageJ v 1.47 h software. For each experimental condition, three independent experiments were performed.

Invasion Assay

To determine the invasion ability of HCC cell lines, transwell membrane filters (8 μ M pore size) (Falcon, Corning, NY, USA) coated by reduced growth factor matrigel (BD, Franklin Lakes,

NJ, USA) were used. 1×10^5 cells were seeded in the upper chamber with 1% FBS medium, 20% FBS medium was added to the bottom chamber. Following 48 h incubation, the cells were removed from the top surface of the membrane. The invasive cells adhering to the bottom surface of the membrane were fixed using 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) and stained with 600 nM DAPI (Thermo Fisher Scientific, Rockford, IL, USA). The total number of DAPI-stained nuclei of invading cells were counted under a fluorescence microscopy by using ImageJ software in five randomly chosen macroscopic fields per membrane. Each experiment was performed in triplicate and was repeated at least three times.

β -galactosidase Assay


All the experiments were performed using the beta-galactosidase staining kit according to manufacturer's instructions (Cell Signaling Technologies - USA, Danvers, MA).


Briefly, 100,000 cells were plated on 35 mm Petri dishes at 37°C in 5% CO₂ overnight, then treated with 300 μ M OA

for up to 48 h. Cells were fixed at 48 h, then 1 ml of beta-galactosidase staining solution was applied to each dish. Cells were incubated overnight in a dry, CO₂-free incubator, then were examined under light microscope at 200x magnification. For the quantification of β -galactosidase positive cells, a score from 1 to 3 was assigned to each cell based on color intensity. The average of the scores of three microscopic fields from each Petri dish was calculated and the values were divided by the overall number of analyzed cells. Each experiment was performed in triplicate and was repeated at least three times.

Statistical Analysis

All the experiments were repeated at least 3 times. Statistical analysis was performed using Prism software (GraphPad). Values are expressed as mean, with individual experiments data points plotting. The statistical significance was determined performing unpaired Student *t*-tests or One-Way Analysis of variance (ANOVA). Student's *t*-test was used for statistical comparison between means where appropriate (two groups) and One-Way





ANOVA (three or more groups); $P \leq 0.05$ was considered statistically significant.

RESULTS

Lipid Accumulation Induced by OA Administration

In order to evaluate the involvement of OA in the modulation of neutral lipid accumulation in human hepatocellular carcinoma and hepatocyte cell lines, we treated Control cell line (THLE-2), Hep3B and Huh7.5 with increasing doses of OA (50, 150, and 300 μM). Upon 24 h treatment, cells were fixed and stained with Oil-Red O dye, which binds neutral lipids, such as triglycerides and cholesterol esters. As shown by optical microscopy analyses, the treatment with increasing doses of OA induced a consistent relevant and dose-dependent Oil-Red O accumulation compared to the basal level into the cytoplasm of both HCC cell lines. Only a slight Oil-Red O staining increase was observed in the control cell line (Figure 1). Oil-Red O quantification by eluate absorbance

normalized by cell number, showed a dose dependent increase with a significant value at 300 μM OA vs. untreated cells in HCC.

Supplementary Figure 1 shows a similar increase of oil-red staining at 48 h, suggesting that there is not a delay in lipid accumulation, rather, a permanent increase is present in cancer cells at 24 and 48 h.

Autophagic Flux and Perilipin-2 Modulation Upon OA Treatment

Since autophagy is known to be involved in tumor metabolism and in LD break-down, we investigated OA effect on autophagy. We treated Control, Hep3B, Huh7.5 with increasing doses of OA and bafilomycin A1. The presence of bafilomycin A1 allows to evaluate the autophagic flux (Klionsky et al., 2016) by blocking the fusion between autophagosome and lysosome and inducing autophagosomes accumulation. As shown in Figure 2A, increasing doses of OA reduce the autophagic flux in a dose dependent manner, in both HCC cell lines. On the contrary, in the control cell line (THLE-2) OA shows no effect. We speculate that the reduction observed in Figure 2 on Hep3B

571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627




FIGURE 3 | OA reduces viability, cyclin D1 and PCNA in HCC cell lines. Cell viability assays and western blot analyses for Cyclin D1 and PCNA were performed. **(A)** OA induced a significant dose-dependent reduction of cellular viability in HCC cell lines but not in healthy hepatocyte cell line, measured by Alamar Blue assay. **(B)** Western blot Cyclin D1 and PCNA analyses showed that OA treatment induced a significant reduction of Cyclin D1 and PCNA levels in HCC cell lines, but not in healthy hepatocytes cell line ($n = 3$; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$).

and Huh7.5 may be associated with the parallel increase observed in **Figure 1**, while the lack of effect in control cell line is consistent in **Figures 1, 2**. In order to better understand the relation between LD accumulation and autophagy, the levels of perilipin-2 were investigated by western blot analyses upon 48 h OA administration. Perilipin-2 is located in LD peripheral zone and its abundance is inversely related to autophagy level in liver (Tsai et al., 2017). In **Figure 2B** perilipin-2 levels in

Control, Hep3B, and Huh7.5 cell lines are shown. 48 h OA treatment led to a significant and dose-dependent increase of perilipin-2 levels in both HCC cell lines. Metabolic and inflammation related targets (Zhong et al., 2018; Gnoni et al., 2019) were differently modulated in HCC cells as compared to control cells thus indicating that OA exerts different effects in healthy vs. HCC cells as a consequence of different lipid accumulation (**Supplementary Figure 2**).

628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684

Q21




FIGURE 4 |

(Continued)

799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855

856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912




FIGURE 4 | OA increases cell death in HCC cell lines but not in healthy hepatocyte cell line. Dead/total cells percentage ratio, western blot analysis for the cleaved forms of caspase-3 and PARP, cytofluorimetric analysis for Ann V/PI as well as β-galactosidase staining were performed. **(A)** Trypan blue staining showed that OA treatment induced cell death in both HCC cell lines, but not in healthy hepatocytes cell line. **(B)** Western blot analysis for the cleaved forms of caspase-3 and PARP
(Continued)

FIGURE 4 | proteins showed that 300 μM OA induced apoptotic cell death in Huh7.5 cell line. **(C,D)** Cytofluorimetric analysis for Ann V/PI staining of Hep3B and Huh7.5 cell lines cultured with different concentration of OA (50, 150, and 300 μM). The strategy of cytometric analysis is showed on the left: representative dot plots from five different experiments, by using PI staining alone for gating Ann V + / PI + cells. On the right, histograms of Ann V - / PI + necrotic cells (fold increase) of Hep3B and Huh7.5 cell lines showed that 300 μM OA significantly induces necrosis in Hep3B ($n = 3$; * $p < 0.05$; ** $p < 0.01$). **(E)** β -galactosidase staining for Control cell line and Hep3B was performed. Images and graphs revealed that 300 μM OA treatment induced significant increase of senescence phenotype in Hep3B but not in Control ($n = 3$; * $p < 0.05$).

These results show that OA treatment directly affects perilipin-2 expression in hepatocellular carcinoma cell lines, correlating with both neutral lipid accumulation and autophagic flux reduction.

Viability and Cell Death Upon OA Treatment

Control, Hep3B and Huh7.5 cells were treated with OA for 48 h to investigate OA effects on viability and cell death. Alamar Blue assay showed a specific dose-dependent reduction of cellular viability in both HCC cell lines (**Figure 3A**). Also, OA-dose-dependently reduced the expression of the proliferation markers cyclin D1 and PCNA in both HCC cell lines but not in healthy controls (**Figure 3B**).

Then, we evaluated cell death by trypan blue cell staining. Forty-eight hours OA treatment induced a significant cell death in both HCC cell lines, but not in the Control cell line (**Figure 4A**). Finally, we investigated two markers of the apoptotic pathway, namely, caspase-3 and PARP. Western blot analyses show that both Caspase-3 and PARP are activated by cleavage in Huh7.5 cell line upon 300 μM OA treatment (**Figure 4B**). Conversely in Hep3B and in Control cells no increase of the active form of Caspase-3 proteins has been observed. Nevertheless, a small sub-G1 population is observed through Flow Cytometry cell cycle analysis after PI staining, suggesting a week apoptotic response in Hep3B (**Supplementary Figure 3**).

We also carried out cytofluorimetric analyses with Annexin V-FITC/PI. As shown in **Figures 4C,D**, increasing doses of OA significantly increase necrosis in Hep3B but not in Huh7.5. Necrosis appears as a dose dependent effect of OA treatment in Hep3B but not in Huh7.5. Finally, as shown in **Figure 4E**, 300 μM OA treatment significantly induced a senescence phenotype in Hep3B cell line, but not in Control cell line.

We therefore concluded that OA may induce cell death and senescence pathways in HCC cell lines.

p-ERK and Anti-apoptotic Proteins Modulation Upon OA Treatment

We then investigated p44/p42 MAPK (ERK1/2) phosphorylation after 48 h OA treatment since reduction of ERK phosphorylation in the Thr202/Tyr204 has been related to reduced proliferation and increased cell death (Hennig et al., 2010). Western blot analyses (**Figure 5A**) show that increasing OA concentrations dose-dependently reduce p-ERK in both HCC cell lines but not in the healthy controls.

To further investigate OA-induced cell death pathways, we treated Control, Hep3B and Huh7.5 cell lines for 48 h with 300 μM OA. Western blot analyses revealed that OA significantly

down-regulated the expression of anti-apoptotic proteins c-Flip (**Figure 5B**) and Bcl-2 (**Figure 5C**) in both HCC cell lines but not in the healthy cells. These data highlight OA as a possible inducer of cell death processes in HCC by modulating cell death regulators (Tsujimoto et al., 1997; Giampietri et al., 2014). Our results are in agreement and extend previous results obtained in different cellular models showing Bcl-2 reduction upon OA treatment (Jiang et al., 2017).

OA Reduces Migration and Invasion of Both HCC Cell Lines


We then performed wound-healing assays to evaluate cell migration. Representative images are shown in **Figure 6** at different times after wound scratch. The percentage of uncovered area at different time points represents the different wound recovery ability of Control, Hep3B and Huh7.5 cell lines. Hep3B cells display higher ability to cover the plate as compared to Huh7.5. Such result is in agreement with previous data demonstrating higher Hep3B cell line aggressiveness as compared to other HCC cell lines (Slany et al., 2010; Qiu et al., 2015). OA (300 μM) significantly reduces the migration of both HCC cell lines (**Figures 6B,C**) as compared to healthy cells (**Figure 6A**). OA appears to be more potent on Hep3B cells, thus indicating the potential utility of OA in aggressive setup.

We then evaluated the OA effect on invasiveness in transwell invasion assays. As shown in **Figure 6D**, a significant 70-to-80% reduction of invasion after 300 μM OA treatment is observed in both HCC cell lines.

The Autophagy Activator Torin-1 Reduces OA-Induced Lipid Accumulation and Cell Death

We then further analyzed the autophagy under OA treatment. Hep3B and Huh7.5 cells were treated with OA combined with torin-1 in the presence of bafilomycin A1. As expected, combined OA/torin-1 treatment increases the autophagic marker LC3II in both HCC cell lines as compared to OA alone (**Figure 7A**). A significant reduction of neutral lipid accumulation was observed, as compared to single OA treatment in HCC cell lines (**Figure 7B**). Interestingly, the neutral lipid storage reduction parallels the significant cell death decrease (**Figure 7C**).

We concluded that OA-induced neutral lipid accumulation and cell death are both dependent on autophagy impairment since the combined OA/torin-1 treatment is able to reduce lipid accumulation and cell death; therefore, OA-dependent anti-tumor effects are dependent, at least in part, on autophagy reduction in HCC cell lines.






FIGURE 6 |

(Continued)




FIGURE 6 | OA reduces migration and invasion of both hepatocarcinoma cell lines. Wound-healing assay on Control (A), Hep3B (B), and Huh7.5 (C) cell lines were performed. Representative phase-contrast images wound-healing assay (scratch test) taken at different time points (0, 24, and 48 h) after 300 μ M OA treatment are shown. Quantitative analysis of the percentage of uncovered area at 48 h revealed a statistical significance difference in both HCC cell lines after OA treatment, while no differences in Control cell line were observed upon OA treatment ($n = 3$; $*p < 0.05$; $**p < 0.01$). (D) Invasion assay of Hep3B and Huh7.5 cell lines was performed. Top: significant reduction of invading cells percentage after 48 h OA treatment in both HCC cell lines. Bottom: Representative images of Hep3b and Huh7.5 DAPI-stained nuclei after 300 μ M OA treatment are shown ($n = 3$; $***p < 0.001$; $****p < 0.0001$).


DISCUSSION

In the last recent years different studies highlighted the role of lipids in tumor progression, namely, in hepatocellular carcinoma. This cancer type, like other tumors, exploits lipid reservoirs to promote its progression (Borchers and Pieler, 2010). OA displays important beneficial effects on the liver, by reducing hepatic steatosis and fibrogenesis. OA plays a positive role in the primary prevention of non-alcoholic fatty liver disease (NAFLD). Intake of monounsaturated fatty acids such as OA, may be beneficial for NAFLD patients, as opposed to the intake of carbohydrates, thus reducing the potential risk to develop HCC (Assy et al., 2009). In addition, the effects of OA in different cancer processes are well-known. OA promotes the growth of highly metastatic tumors (Li et al., 2014) while it induces cell death in low metastatic tumors (Carrillo et al., 2012). OA has been also shown to exert anti-cancer effects in tumors inducing lipotoxicity (Yao et al., 2011). In the present study we investigated the involvement of OA in counteracting HCC growth with a particular focus on autophagy. We addressed this issue on two different HCC cell lines vs. healthy hepatocytes. The two HCC cell lines differ in their morphology, growth and cisplatin sensitivity (Qin and Ng, 2002).

Since fatty acids are able to determine LD accumulation in HCC (Jarc and Petan, 2019), we evaluated neutral lipids and LD content. Surprisingly, we observed (Figure 1) a significant increase in neutral lipid storage in both HCC cell lines, but not in the healthy hepatocyte cell line at 300 μ M OA, assayed through Oil-Red O staining. We therefore concluded that HCC cell lines

display higher attitude to accumulate neutral lipids ad LD as compared to healthy cells. As shown in Figure 2 we also found a specific reduction of autophagy marker LC3II and increased LD marker perilipin-2 in HCC thus hypothesizing that autophagy reduction underlies higher LD and neutral lipid accumulation in HCC upon OA administration. An inverse relationship between perilipin-2 and autophagy levels is known to occur in the liver (Tsai et al., 2017) in agreement with our OA-induced effects.

Reduced Alamar Blue staining in both HCC cell lines upon OA treatment as well as significant cyclin-D1 and PCNA decrease in both HCC cell lines (Figure 3) suggest the role of OA as a negative regulator of proliferation in HCC cell lines. Previous studies reported cell proliferation inhibition and apoptosis induction after OA administration in carcinoma cells (Carrillo et al., 2012). In previous works unsaturated fatty acid oleate (an oleic acid-derived salt) induces (Vinciguerra et al., 2009; Park et al., 2018) or inhibits (Arous et al., 2011; Li et al., 2013) HepG2 cell proliferation in a concentration-dependent manner, with a mechanism only partially elucidated. We report here that increasing doses of OA reduce viability and increase cell death (Figure 4) in both HCC cell lines. OA activates the apoptotic process in Huh7.5 but not in Hep3B and increases necrotic cell percentage in Hep3B but not in Huh7.5. Such data agree with previous observations indicating that OA, among many beneficial functions, can induce cell death through apoptotic (Jiang et al., 2017) and non-apoptotic pathways (Yamakami et al., 2014). Remarkably, as described by Magtanong et al. (2016) there are several non-apoptotic cell death pathways activated



1483 by OA, such as necroptosis. OA is known to modulate cell
1484 death by altering lipid metabolism or by altering membrane lipid
1485 composition (Fontana et al., 2013; Ning et al., 2019).

1486 Recently, Bosc et al. (2020) demonstrated that autophagy
1487 regulates fatty acids availability through mitochondria-
1488 endoplasmic reticulum contact sites and this event occurs
1489 mainly in cancer cells. The metastatic potential of cancer cells is
1490 related to genes involved in fatty acids synthesis and intracellular
1491 lipids storage. Therefore, modulation of lipid accumulation,
1492 function of enzymes dedicated to LD digestion, and fatty
1493 acids availability play together a role in tumor progression
1494 (Sanchez-Martinez et al., 2015; Giampietri et al., 2020). In
1495 fact, lipid metabolism generates a high energy support used
1496 by cancer cells to grow and metastasize. It is important to
1497 note that OA accumulates inside the cell as triglycerides and
1498 cholesterol esters, resulting in LD formation, i.e., cellular
1499 organelles important in lipotoxicity control (Wen et al., 2013;
1500 Petan et al., 2018). Interfering with LD accumulation leads to cell
1501 death in fibroblasts exposed to the otherwise non-toxic oleate
1502 (Listenberger et al., 2003).

1503 We report here a senescent phenotype in β -galactosidase
1504 stained Hep3B after OA treatment (Figure 4). This result is
1505 in accordance with our data showing that Hep3B cell line
1506 does not undergo apoptosis but necrosis after OA treatment.
1507 Different factors are known to regulate cellular senescence
1508 and cells displaying G1 or G2 phase increase with S-phase
1509 reduction may enter a senescent state becoming resistant to
1510 apoptotic signals and undergoing necrosis (Kastan and Bartek,
1511 2004; Gire and Dulic, 2015). Furthermore, senescence observed
1512 on OA-treated Hep3B is in accordance with previous reports
1513 demonstrating OA as a mild senescence inducer (Iwasa et al.,
1514 2003; Yamakami et al., 2014). Further studies are underway to
1515 further evaluate cell death processes induced by OA in HCC
1516 cell lines. We therefore concluded that in our experimental
1517 setup OA activates both apoptotic (Jiang et al., 2017) and
1518 non-apoptotic pathways (Assy et al., 2009), depending on
1519 cell type.

1520 We observed that OA treatment displays significant reduction
1521 of c-Flip and Bcl-2 in both HCC cell lines but not in the
1522 healthy hepatocyte cell line (Figure 5). Wang et al. described the
1523 anti-apoptotic role of both these proteins in the liver (Wang,
1524 2015). It is well-known that c-Flip has multiple roles, modulating
1525 apoptosis, autophagy and necrosis (Safa, 2013). Its up-regulation
1526 was correlated with a poor clinical outcome in many pathological
1527 conditions including cancer. Moreover, agents or molecules
1528 able to inhibit c-Flip expression are of potential therapeutic
1529 interest (Safa, 2013). Bcl-2 is known for its properties in cell
1530 death modulation and OA has been shown to reduce Bcl-2
1531 expression levels in tongue squamous carcinoma cells (Jiang et al.,
1532 2017). In accordance with our results showing OA-dependent
1533 cyclin D1 decrease and cell death activation, we also found
1534 dose-dependent OA p-ERK reduction, reported in Figure 5.
1535 This finding parallels results obtained in tongue squamous cell
1536 carcinoma cells, where dose-dependent OA treatment reduced p-
1537 ERK1/2 (Jiang et al., 2017). In the present study OA significantly
1538 reduced the migratory capability of HCC cells as compared to
1539 Control cells (THLE-2) and reduced the number of invading

1540 cells in both HCC cell lines (Figure 6). Hep3B cells display
1541 higher ability to cover the scratch respect to Huh7.5 cells.
1542 This difference between the two cell lines is in agreement with
1543 previous data indicating higher aggressiveness of Hep3B cell line
1544 vs. other HCC cell lines. Taken together these data supported
1545 the hypothesis that OA, by negatively modulating the autophagic
1546 flux, counteracts the aggressiveness and invasiveness of Hep3B
1547 and Huh7.5 cell lines.

1548 OA treatment in hepatic cell lines like HepG2 or immortalized
1549 hepatocytes induces lipid accumulation and represents an *in vitro*
1550 model of liver disease (Lim et al., 2020). Under our experimental
1551 conditions, OA treatment induces lipid accumulation as expected
1552 in healthy cells (THLE-2), although at a lower extent as compared
1553 to cancer cells (Hep3B and Huh7.5). This suggests a beneficial
1554 role of OA in cancers cells since the higher lipid accumulation
1555 observed in cancer cells leads to cell death and to reduced
1556 proliferation, migration, and invasion. We demonstrate that this
1557 is likely related to autophagy flux reduction in cancer cells.
1558 These results agree with Li et al. (2013), who demonstrated
1559 that reduced invasiveness of HCC cells (HepG2 and BEL7402)
1560 is related to a negative modulation of autophagy. To verify
1561 the role of autophagy in OA-dependent effects, HCC cells
1562 were treated with OA and analyzed for LD content in the
1563 presence of the autophagy inducer Torin-1 (a mTOR kinase
1564 inhibitor). The results shown in Figure 7 led us to conclude
1565 that 300 μ M OA-induced LD accumulation and cell death are
1566 both, at least partially, dependent on autophagy impairment
1567 since the combined torin-1/OA treatment reduces LD and
1568 cell death. Previous studies demonstrated that OA treatment
1569 reduces autophagy in Hepa1c1c7 mouse hepatoma cell line
1570 (Ning et al., 2019); also the saturated palmitic acid (PA)
1571 impairs autophagic-flux in a time-dependent manner in liver
1572 HepG2 cells (Korovila et al., 2020). Furthermore, OA was
1573 previously shown to exert different effects in HepG2 cells
1574 at different concentrations (Pang et al., 2018). In particular
1575 LD accumulation and apoptosis induction was reported at
1576 concentrations ranging from 0.1 to 2 mM OA while LD reduction
1577 was found at 400 μ M OA treatment. The Authors concluded
1578 that these concentration-dependent effects are strictly related
1579 to autophagy since autophagy is able to prevent 400 μ M
1580 OA-induced HepG2 apoptosis.

1581 Results of the present study achieved on three human cell
1582 lines-based *in vitro* systems, confirm the pivotal role of autophagy
1583 reduction in promoting OA-dependent LD accumulation, cell
1584 death and reduced aggressiveness/invasiveness. Additional
1585 studies are needed to further clarify the underlying molecular
1586 mechanisms. We conclude that OA stimulates HCC cell death
1587 via autophagy reduction while it does not impair autophagy
1588 level in healthy cells thus leading us to hypothesize that
1589 fine autophagy regulation preserves healthy hepatocytes
1590 resistance to toxicity caused by high levels of neutral
1591 lipids. LD accumulation in association with autophagic
1592 flux reduction after OA treatments in Hep3B and Huh7.5
1593 cell lines, promote cell death through apoptosis in Huh7.5
1594 and also non-apoptotic pathway in Hep3B cell line. Such
1595 differences in cell death mechanisms are currently under
1596 further investigation.

In conclusion, we present here several evidences indicating OA specific antitumor effects in HCC in an autophagy-dependent manner.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

FG, SP, and CG conceived the study. FG performed the majority of the experiments and analyzed the data. SM and AD'A performed flow cytometry analyses. LT and VF supported FG in performing some experiments. FG and CG wrote the manuscript supervised by AF, EG, and EZ. All authors contributed to the article and approved the submitted version.

REFERENCES

- Amir, M., and Czaja, M. J. (2011). Autophagy in nonalcoholic steatohepatitis. *Expert Rev. Gastroenterol. Hepatol.* 5, 159–166. doi: 10.1586/egh.11.4
- Arous, C., Naimi, M., and Van Obberghen, E. (2011). Oleate-mediated activation of phospholipase D and mammalian target of rapamycin (mTOR) regulates proliferation and rapamycin sensitivity of hepatocarcinoma cells. *Diabetologia* 54, 954–964. doi: 10.1007/s00125-010-2032-1
- Assy, N., Nassar, F., Nasser, G., and Grosovski, M. (2009). Olive oil consumption and non-alcoholic fatty liver disease. *World J. Gastroenterol.* 15, 1809–1815. doi: 10.3748/wjg.15.1809
- Borchers, A., and Pieler, T. (2010). Programming pluripotent precursor cells derived from *Xenopus* embryos to generate specific tissues and organs. *Genes* 1, 413–426. doi: 10.3390/genes1030413
- Bosc, C., Broin, N., Fanjul, M., Saland, E., Farge, T., Courdy, C., et al. (2020). Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. *Nat. Commun.* 11:4056. doi: 10.1038/s41467-020-17882-2
- Carrillo, C., Cavia Mdel, M., and Alonso-Torre, S. R. (2012). Antitumor effect of oleic acid; mechanisms of action: a review. *Nutr. Hosp.* 27, 1860–1865.
- Chava, S., Lee, C., Aydin, Y., Chandra, P. K., Dash, A., Chedid, M., et al. (2017). Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. *Oncotarget* 8, 40019–40036. doi: 10.18632/oncotarget.16685
- D'Arcangelo, D., Giampietri, C., Muscio, M., Scatozza, F., Facchiano, F., and Facchiano, A. (2018). WIP1, BAG1, and PEX3 autophagy-related genes are relevant melanoma markers. *Oxid. Med. Cell. Longev.* 2018:1471682. doi: 10.1155/2018/1471682
- Denton, D., Nicolson, S., and Kumar, S. (2012). Cell death by autophagy: facts and apparent artefacts. *Cell Death Differ.* 19, 87–95. doi: 10.1038/cdd.2011.146
- Ding, Z. B., Hui, B., Shi, Y. H., Zhou, J., Peng, Y. F., Gu, C. Y., et al. (2011). Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. *Clin. Cancer Res.* 17, 6229–6238. doi: 10.1158/1078-0432.CCR-11-0816
- Fontana, A., Spolaore, B., and Polverino De Laureto, P. (2013). The biological activities of protein/oleic acid complexes reside in the fatty acid. *Biochim. Biophys. Acta* 1834, 1125–1143. doi: 10.1016/j.bbapap.2013.02.041
- Fujimoto, Y., Onoduka, J., Homma, K. J., Yamaguchi, S., Mori, M., Higashi, Y., et al. (2006). Long-chain fatty acids induce lipid droplet formation in a cultured human hepatocyte in a manner dependent of acyl-coa synthetase. *Biol. Pharm. Bull.* 29, 2174–2180. doi: 10.1248/bpb.29.2174
- Giampietri, C., Petrunaro, S., Coluccia, P., Antonangeli, F., Paone, A., Padula, F., et al. (2006). c-Flip(L) is expressed in undifferentiated mouse male germ cells. *FEBS Lett.* 580, 6109–6114. doi: 10.1016/j.febslet.2006.10.010

FUNDING

This work was supported by Progetti di Ricerca di Ateneo (Sapienza University of Rome, Italy).

ACKNOWLEDGMENTS

The authors are grateful to Prof. Cinzia Fabrizi and Dr. Silvia Sideri from the Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy for suggestions and technical support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcell.2021.629182/full#supplementary-material>

- Giampietri, C., Petrunaro, S., Cordella, M., Tabolacci, C., Tomaipitina, L., Facchiano, A., et al. (2017). Lipid storage and autophagy in melanoma cancer cells. *Int. J. Mol. Sci.* 18:1271. doi: 10.3390/ijms18061271
- Giampietri, C., Starace, D., Petrunaro, S., Filippini, A., and Ziparo, E. (2014). Necroptosis: molecular signalling and translational implications. *Int. J. Cell Biol.* 2014:490275. doi: 10.1155/2014/490275
- Giampietri, C., Tomaipitina, L., Scatozza, F., and Facchiano, A. (2020). Expression of genes related to lipid handling and the obesity paradox in melanoma: database analysis. *JMIR Cancer* 6:e16974. doi: 10.2196/16974
- Gire, V., and Dulic, V. (2015). Senescence from G2 arrest, revisited. *Cell Cycle* 14, 297–304. doi: 10.1080/15384101.2014.1000134
- Gnoni, A., Siculella, L., Paglialonga, G., Damiano, F., and Giudetti, A. M. (2019). 3,5-diiodo-L-thyronine increases de novo lipogenesis in liver from hypothyroid rats by SREBP-1 and ChREBP-mediated transcriptional mechanisms. *IUBMB Life* 71, 863–872. doi: 10.1002/iub.2014
- Hennig, M., Yip-Schneider, M. T., Wentz, S., Wu, H., Hekmatyar, S. K., Klein, P., et al. (2010). Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth *in vitro* and in mouse model systems. *Hepatology* 51, 1218–1225. doi: 10.1002/hep.23470
- Iwasa, H., Han, J., and Ishikawa, F. (2003). Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. *Genes Cells* 8, 131–144. doi: 10.1046/j.1365-2443.2003.00620.x
- Jarc, E., and Petan, T. (2019). Lipid droplets and the management of cellular stress. *Yale J. Biol. Med.* 92, 435–452.
- Jiang, L., Wang, W., He, Q., Wu, Y., Lu, Z., Sun, J., et al. (2017). Oleic acid induces apoptosis and autophagy in the treatment of tongue squamous cell carcinomas. *Sci. Rep.* 7:11277. doi: 10.1038/s41598-017-11842-5
- Kastan, M. B., and Bartek, J. (2004). Cell-cycle checkpoints and cancer. *Nature* 432, 316–323. doi: 10.1038/nature03097
- Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., et al. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12, 1–222. doi: 10.1080/15548627.2015.1100356
- Korovila, I., Jung, T., Deubel, S., Grune, T., and Ott, C. (2020). Punicalagin attenuates palmitate-induced lipid droplet content by simultaneously improving autophagy in hepatocytes. *Mol. Nutr. Food Res.* 64:e2000816. doi: 10.1002/mnfr.202000816
- Li, J., Yang, B., Zhou, Q., Wu, Y., Shang, D., Guo, Y., et al. (2013). Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. *Carcinogenesis* 34, 1343–1351. doi: 10.1093/carcin/bgt063
- Li, S., Zhou, T., Li, C., Dai, Z., Che, D., Yao, Y., et al. (2014). High metastatic gastric and breast cancer cells consume oleic acid in an AMPK dependent manner. *PLoS ONE* 9:e97330. doi: 10.1371/journal.pone.0097330

- 1711 Lim, D. W., Jeon, H., Kim, M., Yoon, M., Jung, J., Kwon, S., et al.
1712 (2020). Standardized rice bran extract improves hepatic steatosis in
1713 HepG2 cells and ovariectomized rats. *Nutr. Res. Pract.* 14, 568–579.
1714 doi: 10.4162/nrp.2020.14.6.568
- 1715 Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Jr Ory,
1716 D. S., et al. (2003). Triglyceride accumulation protects against fatty acid-
1717 induced lipotoxicity. *Proc. Natl. Acad. Sci. U. S. A.* 100, 3077–3082.
1718 doi: 10.1073/pnas.0630588100
- 1719 Maan, M., Peters, J. M., Dutta, M., and Patterson, A. D. (2018). Lipid metabolism
1720 and lipophagy in cancer. *Biochem. Biophys. Res. Commun.* 504, 582–589.
1721 doi: 10.1016/j.bbrc.2018.02.097
- 1722 Magtanong, L., Ko, P. J., and Dixon, S. J. (2016). Emerging roles for lipids in non-
1723 apoptotic cell death. *Cell Death Differ.* 23, 1099–1109. doi: 10.1038/cdd.2016.25
- 1724 Mizushima, N. (2007). Autophagy: process and function. *Genes Dev.* 21,
1725 2861–2873. doi: 10.1101/gad.1599207
- 1726 Ning, J., Zhao, C., Chen, J. X., and Liao, D. F. (2019). Oleate inhibits hepatic
1727 autophagy through p38 mitogen-activated protein kinase (MAPK). *Biochem.
1728 Biophys. Res. Commun.* 514, 92–97. doi: 10.1016/j.bbrc.2019.04.073
- 1729 Pang, L., Liu, K., Liu, D., Lv, F., Zang, Y., Xie, F., et al. (2018). Differential effects
1730 of reticulophagy and mitophagy on nonalcoholic fatty liver disease. *Cell Death
1731 Dis.* 9:90. doi: 10.1038/s41419-017-0136-y
- 1732 Park, S., Park, J. H., Jung, H. J., Jang, J. H., Ahn, S., Kim, Y., et al.
1733 (2018). A secretome profile indicative of oleate-induced proliferation
1734 of HepG2 hepatocellular carcinoma cells. *Exp. Mol. Med.* 50:93.
1735 doi: 10.1038/s12276-018-0120-3
- 1736 Perdomo, L., Beneit, N., Otero, Y. F., Escribano, O., Diaz-Castroverde, S., Gomez-
1737 Hernandez, A., et al. (2015). Protective role of oleic acid against cardiovascular
1738 insulin resistance and in the early and late cellular atherosclerotic process.
1739 *Cardiovasc. Diabetol.* 14:75. doi: 10.1186/s12933-015-0237-9
- 1740 Perez-Martinez, P., Garcia-Rios, A., Delgado-Lista, J., Perez-Jimenez, F., and
1741 Lopez-Miranda, J. (2011). Mediterranean diet rich in olive oil and obesity,
1742 metabolic syndrome and diabetes mellitus. *Curr. Pharm. Des.* 17, 769–777.
1743 doi: 10.2174/138161211795428948
- 1744 Petan, T., Jarc, E., and Jusovic, M. (2018). Lipid droplets in cancer: guardians of fat
1745 in a stressful world. *Molecules* 23:1941. doi: 10.3390/molecules23081941
- 1746 Pfeifer, A. M., Cole, K. E., Smoot, D. T., Weston, A., Groopman, J. D., Shields,
1747 P. G., et al. (1993). Simian virus 40 large tumor antigen-immortalized
1748 normal human liver epithelial cells express hepatocyte characteristics and
1749 metabolize chemical carcinogens. *Proc. Natl. Acad. Sci. U. S. A.* 90, 5123–5127.
1750 doi: 10.1073/pnas.90.11.5123
- 1751 Qin, L. F., and Ng, I. O. (2002). Induction of apoptosis by cisplatin and its effect on
1752 cell cycle-related proteins and cell cycle changes in hepatoma cells. *Cancer Lett.*
1753 175, 27–38. doi: 10.1016/S0304-3835(01)00720-0
- 1754 Qiu, G. H., Xie, X., Xu, F., Shi, X., Wang, Y., and Deng, L. (2015). Distinctive
1755 pharmacological differences between liver cancer cell lines HepG2 and Hep3B.
1756 *Cytotechnology* 67, 1–12. doi: 10.1007/s10616-014-9761-9
- 1757 Rebouissou, S., and Nault, J. C. (2020). Advances in molecular classification
1758 and precision oncology in hepatocellular carcinoma. *J. Hepatol.* 72, 215–229.
1759 doi: 10.1016/j.jhep.2019.08.017
- 1760 Rohwedder, A., Zhang, Q., Rudge, S. A., and Wakelam, M. J. (2014). Lipid droplet
1761 formation in response to oleic acid in Huh-7 cells is mediated by the fatty acid
1762 receptor FFAR4. *J. Cell Sci.* 127 (Pt 14), 3104–3115. doi: 10.1242/jcs.145854
- 1763 Safa, A. R. (2013). Roles of c-FLIP in apoptosis, necroptosis, and autophagy. *J.
1764 Carcinog. Mutagen.* (Suppl. 6):003. doi: 10.4172/2157-2518.S6-003
- 1765 Sales-Campos, H., Souza, P. R., Peghini, B. C., Da Silva, J. S., and Cardoso, C. R.
1766 (2013). An overview of the modulatory effects of oleic acid in health and disease.
1767 *Mini. Rev. Med. Chem.* 13, 201–210. doi: 10.2174/138955713804805193
- 1768 Sanchez-Martinez, R., Cruz-Gil, S., Gomez de Cedron, M., Alvarez-Fernandez,
1769 M., Vargas, T., Molina, S., et al. (2015). A link between lipid metabolism and
1770 epithelial-mesenchymal transition provides a target for colon cancer therapy. *1771
1772 Oncotarget* 6, 38719–38736. doi: 10.18632/oncotarget.5340
- 1773 Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., et al.
1774 (2009). Autophagy regulates lipid metabolism. *Nature* 458, 1131–1135.
1775 doi: 10.1038/nature07976
- 1776 Slany, A., Haudek, V. J., Zwickl, H., Gundacker, N. C., Grusch, M., Weiss, T. S.,
1777 et al. (2010). Cell characterization by proteome profiling applied to primary
1778 hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. *J. Proteome. Res.* 9,
1779 6–21. doi: 10.1021/pr900057t
- 1780 Taib, B., Aboussalah, A. M., Moniruzzaman, M., Chen, S., Haughey, N. J., Kim, S.
1781 F., et al. (2019). Lipid accumulation and oxidation in glioblastoma multiforme.
1782 *Sci. Rep.* 9:19593. doi: 10.1038/s41598-019-55985-z
- 1783 Tomaipitnca, L., Mandatori, S., Mancinelli, R., Giulitti, F., Petrungraro, S., Moresi,
1784 V., et al. (2019). The role of autophagy in liver epithelial cells and its impact on
1785 systemic homeostasis. *Nutrients* 11:827. doi: 10.3390/nu11040827
- 1786 Tsai, T. H., Chen, E., Li, L., Saha, P., Lee, H. J., Huang, L. S., et al. (2017).
1787 The constitutive lipid droplet protein PLIN2 regulates autophagy in liver.
1788 *Autophagy* 13, 1130–1144. doi: 10.1080/15548627.2017.1319544
- 1789 Tsujimoto, Y., Shimizu, S., Eguchi, Y., Kamiike, W., and Matsuda, H. (1997). Bcl-2
1790 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common
1791 mediators in apoptotic and necrotic signal transduction pathways. *Leukemia*
1792 11(Suppl. 3), 380–382.
- 1793 Vinciguerra, M., Carrozzino, F., Peyrou, M., Carlone, S., Montesano, R., Benelli,
1794 R., et al. (2009). Unsaturated fatty acids promote hepatoma proliferation
1795 and progression through downregulation of the tumor suppressor PTEN. *J.
1796 Hepatol.* 50, 1132–1141. doi: 10.1016/j.jhep.2009.01.027
- 1797 Wang, K. (2015). Autophagy and apoptosis in liver injury. *Cell Cycle* 14,
1798 1631–1642. doi: 10.1080/15384101.2015.1038685
- 1799 Wen, H., Glomm, W. R., and Halskau, O. (2013). Cytotoxicity of
1800 bovine alpha-lactalbumin: oleic acid complexes correlates with the
1801 disruption of lipid membranes. *Biochim. Biophys. Acta* 1828, 2691–2699.
1802 doi: 10.1016/j.bbamem.2013.07.026
- 1803 Yamakami, Y., Miki, K., Yonekura, R., Kudo, I., Fujii, M., and Ayusawa, D.
1804 (2014). Molecular basis for premature senescence induced by surfactants
1805 in normal human cells. *Biosci. Biotechnol. Biochem.* 78, 2022–2029.
1806 doi: 10.1080/09168451.2014.946391
- 1807 Yao, H. R., Liu, J., Plumeri, D., Cao, Y. B., He, T., Lin, L., et al. (2011). Lipotoxicity
1808 in HepG2 cells triggered by free fatty acids. *Am. J. Transl. Res.* 3, 284–291.
- 1809 Zeng, X., Zhu, M., Liu, X., Chen, X., Yuan, Y., Li, L., et al. (2020). Oleic acid
1810 ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of
1811 ER stress and pyroptosis. *Nutr. Metab.* 17:11. doi: 10.1186/s12986-020-0434-8
- 1812 Zhong, J., Gong, W., Chen, J., Qing, Y., Wu, S., Li, H., et al. (2018).
1813 Micheliolide alleviates hepatic steatosis in db/db mice by inhibiting
1814 inflammation and promoting autophagy via PPAR-gamma-mediated NF-small
1815 ka, CyrilllicB and AMPK/mTOR signaling. *Int. Immunopharmacol.* 59, 197–208.
1816 doi: 10.1016/j.intimp.2018.03.036

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Giulitti, Petrungraro, Mandatori, Tomaipitnca, de Franchis, D'Amore, Filippini, Gaudio, Ziparo and Giampietri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.